Literature review
| Research | Year | Number of patients studied/control group | Results |
|---|---|---|---|
| Wiltfang et al. [15] | 1999 | 36/no control group | S100B serum level has advantage over ammonia serum level in detecting portal-systemic encephalopathy |
| Vaquero et al. [16] | 2003 | 54/no control group | S100B serum level has no correlation with HE severity and liver function |
| Saleh et al. [17] | 2007 | 43/9 | S100B level has correlation with HE (stages I and II), compared to healthy and cirrhotic patients without HE |
| Isobe-Harima et al. [18] | 2008 | 9/no control group | S100B serum level is higher in HE patients |
| Duarte Rojo et al. [19] | 2016 | 46/15 | S100B serum levels are higher in patients with cirrhosis and HE than in healthy subjects |
| Toney et al. [21] | 2019 | 82/no control group | no correlation between serum S100B level and severity of HE |
| Strebel et al. [20] | 2020 | 30/no control group | serum S100B protein level correlated with the presence of HE |
Qualification of hepatic encephalopathy; WHC - West Haven Classification, ISHEN - International Society for Hepatic Encephalopathy_
| CONNECTION WITH THE UNDERLYING DISEASE | DURATION | PRESENCE OF TRIGGERING FACTORS WHC | SEVERITY OF CLINICAL MANIFESTATION | ||
|---|---|---|---|---|---|
| ISHEN | |||||
| type A | acute liver failure | episodic | with triggering factors | minimal | covert |
| type B | portosystemic bypass | persistent | I | ||
| without triggering factors | II | overt | |||
| type C | hepatic cirrhosis | recurrent | III | ||
| IV | |||||